ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.909,94
0,99%
Brent Oil
84,85
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Elicio Therapeutics Inc (ELTX)

  7. Elicio Therapeutics Inc (ELTX) Notícias

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ELTX
DataHoraFonteTítuloCódigoCompanhia
28/06/202410:00GlobeNewswire Inc.Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public OfferingNASDAQ:ELTXElicio Therapeutics Inc
27/06/202417:05GlobeNewswire Inc.Elicio Therapeutics Announces Proposed Public OfferingNASDAQ:ELTXElicio Therapeutics Inc
27/06/202417:01GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7PNASDAQ:ELTXElicio Therapeutics Inc
18/06/202409:30GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
12/06/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
03/06/202418:24Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
03/06/202417:41Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ELTXElicio Therapeutics Inc
23/05/202418:30GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
15/05/202417:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
15/05/202417:30GlobeNewswire Inc.Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
25/04/202409:30GlobeNewswire Inc.Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
05/04/202417:30GlobeNewswire Inc.Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
29/03/202409:30GlobeNewswire Inc.Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
18/03/202409:00GlobeNewswire Inc.Elicio Therapeutics Announces $6.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
05/02/202410:30GlobeNewswire Inc.Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ELTXElicio Therapeutics Inc
25/01/202411:00GlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsNASDAQ:ELTXElicio Therapeutics Inc
17/01/202410:30GlobeNewswire Inc.Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumNASDAQ:ELTXElicio Therapeutics Inc
16/01/202410:30GlobeNewswire Inc.Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:ELTXElicio Therapeutics Inc
11/01/202410:30GlobeNewswire Inc.Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyNASDAQ:ELTXElicio Therapeutics Inc
09/01/202408:00GlobeNewswire Inc.Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002NASDAQ:ELTXElicio Therapeutics Inc
22/12/202311:00GlobeNewswire Inc.Elicio Therapeutics Announces $7.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
04/12/202310:00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:ELTXElicio Therapeutics Inc
09/11/202318:30GlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
03/11/202317:30GlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
11/10/202309:00GlobeNewswire Inc.Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
27/09/202318:30GlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
07/09/202309:00GlobeNewswire Inc.Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesNASDAQ:ELTXElicio Therapeutics Inc
06/09/202309:00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
05/09/202309:00GlobeNewswire Inc.Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
28/08/202309:00GlobeNewswire Inc.Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of BiometricsNASDAQ:ELTXElicio Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ELTX

Seu Histórico Recente

TG
A287Y8
Groupe Bruxelles Lambert
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados